Research breakthroughs begin with questions—and the commitment to finding answers. In August 2025, The IBC Network Foundation proudly awarded a $100,000 research grant toDr. Filipa Lynce at Dana-Farber Cancer Institute to support an innovative study investigating the...
Editor’s Note: This article was developed from a podcast conversation and has been edited for clarity, readability, and length while preserving the original insights and intent of the discussion. In recent months, many inflammatory breast cancer (IBC) patients...
Blog by Trish Vickery On April 11, the Dana Farber IBC team held their annual patient forum; the virtual format allowed patients near and far to join. The day included informative medical presentations, followed by an expert roundtable, with a new feature –...
Guest blog post by: Alisa Shorago, J.D., IBC Patient Advocate and Survivor What: The Metastatic Breast Cancer Access to Care Act is currently stuck in committees – in fact, the House of Representatives sent its version there over a year ago. Last time, the bill made...
The FDA has approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. Angela Alexander, PhD, Sr Clinical Studies Coordinator –...
